Shots:

• The companies collaborated to develop liquid biopsy-based CDx based on NGS technology to complement Inovio's therapies. The collaboration initially focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from VGX-3100
• QIAGEN's bioinformatic expertise will raise the predictive biomarker power in Inovio's patient selection. The assay will now be developed for use on the Illumina NextSeq 550Dx platform
• VGX-3100 is a late-stage DNA immunotherapy- currently in two P-III trials (REVEAL 1 & 2) and has the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with the virus

 ­ Ref: PRNewswire | Image: NBC 7 San Diego